A New Method for Faster Backpropagation Learning

Yuan Zeng Ren,Shen Xiaohui 대한전자공학회 1994 ICONIP : International Conference On Neural Inform Vol.3 No.2

A New Method for Faster Back-Propagation Learning

Yuan Zeng Ren,Shen Xiao Hui 대한전자공학회 1994 ICONIP : International Conference On Neural Inform Vol.3 No.1

High-mass Star Formation through Filamentary Collapse and Clump-fed Accretion in G22

Yuan, Jinghua,Li, Jin-Zeng,Wu, Yuefang,Ellingsen, Simon P.,Henkel, Christian,Wang, Ke,Liu, Tie,Liu, Hong-Li,Zavagno, Annie,Ren, Zhiyuan,Huang, Ya-Fang American Astronomical Society 2018 The Astrophysical journal Vol.852 No.1

<P>How mass is accumulated from cloud-scale down to individual stars is a key open question in understanding highmass star formation. Here, we present the mass accumulation process in a hub-filament cloud G22 that is composed of four supercritical filaments. Velocity gradients detected along three filaments indicate that they are collapsing with a total mass infall rate of about 440M(circle dot) Myr(-1), suggesting the hub mass would be doubled in six free-fall times, adding up to similar to 2 Myr. A fraction of the masses in the central clumps C1 and C2 can be accounted for through large-scale filamentary collapse. Ubiquitous blue profiles in HCO+. (3-2) and (CO)-C-13. (3-2) spectra suggest a clump-scale collapse scenario in the most massive and densest clump C1. The estimated infall velocity and mass infall rate are 0.31 km s(-1) and 7.2 x. 10(-4)M(circle dot) yr(-1), respectively. In clump C1, a hot molecular core (SMA1) is revealed by the Submillimeter Array observations and an outflow-driving high-mass protostar is located at the center of SMA1. The mass of the protostar is estimated to be 11-15M(circle dot) and it is still growing with an accretion rate of 7 x. 10(-5)M(circle dot) yr(-1). The coexistent infall in filaments, clump C1, and the central hot core in G22 suggests that pre-assembled mass reservoirs (i.e., high-mass starless cores) may not be required to form high-mass stars. In the course of high-mass star formation, the central protostar, the core, and the clump can simultaneously grow in mass via core-fed/disk accretion, clump-fed accretion, and filamentary/cloud collapse.</P>

Therapeutic effects of traditional Chinese medicine (Maxingshigan-Weijing Decoction) on COVID-19: An open-label randomized controlled trial

Congcong Zeng,Zhengzhong Yuan,Jiahui Zhu,Yintong Wang,Yongyong Xie,Ren Ye,Jinguo Cheng 한국한의학연구원 2021 Integrative Medicine Research Vol.10 No.-

Background Wenzhou has achieved great progress in the prevention and control of the growing coronavirus disease 2019 (COVID-19) pandemic, and traditional Chinese medicine (TCM) has played an indispensable role in this fight. This study aimed to investigate the efficacy of Maxingshigan-Weijing decoction (MWD) in treating infected patients. Methods This study was an open-label randomized controlled trial. Inpatients with mild or moderate symptoms caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were randomly treated with routine supportive care alone or a combination of routine supportive care and MWD. The primary outcome was the rate of symptom (fever, fatigue, cough and difficulty breathing) recovery. Results Fifty-nine inpatients were enrolled, of whom 29 received routine supportive care alone (control group) and 30 received combination therapy (treatment group). The rate of symptom recovery was significantly higher in the treatment group than in the control group. The time to recovery of fever (3 vs. 7 days), fatigue (9 vs. 12 days), coughing (9 vs. 14 days) and difficulty breathing (4.5 vs. 9.5 days) was also significantly shorter in the treatment group (all p < 0.001). The syndrome score was lower after MWD treatment. However, neither group differed in the viral assay findings, hospitalization days, medication time or the rate of conversion to severe cases. Conclusions MWD increased the rate of symptom recovery and shortened the time to recovery of clinical symptoms without deterioration to death or critical care. These findings may provide opportunities for the use of complementary medicine in treating this infection. Clinical trial registration Chinese Clinical Trial Registry, ChiCTR2000030759. Background Wenzhou has achieved great progress in the prevention and control of the growing coronavirus disease 2019 (COVID-19) pandemic, and traditional Chinese medicine (TCM) has played an indispensable role in this fight. This study aimed to investigate the efficacy of Maxingshigan-Weijing decoction (MWD) in treating infected patients. Methods This study was an open-label randomized controlled trial. Inpatients with mild or moderate symptoms caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were randomly treated with routine supportive care alone or a combination of routine supportive care and MWD. The primary outcome was the rate of symptom (fever, fatigue, cough and difficulty breathing) recovery. Results Fifty-nine inpatients were enrolled, of whom 29 received routine supportive care alone (control group) and 30 received combination therapy (treatment group). The rate of symptom recovery was significantly higher in the treatment group than in the control group. The time to recovery of fever (3 vs. 7 days), fatigue (9 vs. 12 days), coughing (9 vs. 14 days) and difficulty breathing (4.5 vs. 9.5 days) was also significantly shorter in the treatment group (all p < 0.001). The syndrome score was lower after MWD treatment. However, neither group differed in the viral assay findings, hospitalization days, medication time or the rate of conversion to severe cases. Conclusions MWD increased the rate of symptom recovery and shortened the time to recovery of clinical symptoms without deterioration to death or critical care. These findings may provide opportunities for the use of complementary medicine in treating this infection. Clinical trial registration Chinese Clinical Trial Registry, ChiCTR2000030759.

Complement Receptor 1 Expression in Peripheral Blood Mononuclear Cells and the Association with Clinicopathological Features And Prognosis of Nasopharyngeal Carcinoma

He, Jian-Rong,Xi, Jing,Ren, Ze-Fang,Qin, Han,Zhang, Ying,Zeng, Yi-Xin,Mo, Hao-Yuan,Jia, Wei-Hua Asian Pacific Journal of Cancer Prevention 2012 Asian Pacific journal of cancer prevention Vol.13 No.12

Purpose: Complement receptor 1 (CR1) is induced by Epstein-Barr virus (EBV) and may be a potential biomarker of nasopharyngeal carcinoma (NPC). We conducted the present study to evaluate the association of CR1 expression with clinicopathological features and prognosis of NPC. Methods: We enrolled 145 NPC patients and 110 controls. Expression levels of CR1 in peripheral blood mononuclear cells (PBMCs) were detected using quantitative real-time PCR and associations with clinicopathological features and prognosis were examined. Results: CR1 levels in the NPC group [3.54 (3.34, 3.79)] were slightly higher than those in the controls [3.33 (3.20, 3.47)] (P<0.001). Increased CR1 expression was associated with histology classification (type III vs. type II, P=0.002), advanced clinical stage (P=0.003), high T stage (P=0.017), and poor overall survival (HR, 4.89; 95% CI, 1.23-19.42; P=0.024). However, there were no statistically significant differences in CR1 expression among N or M stages. Conclusion: These findings indicate that CR1 expression in PBMCs may be a new biomarker for prognosis of NPC and a potential therapeutic target.

Decreased Expression of FADS1 Predicts a Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma

Du, Yong,Yan, Shu-Mei,Gu, Wan-Yi,He, Fan,Huang, Li-Yun,Li, Mei,Yuan, Yan,Chen, Ren-Hui,Zhong, Qian,Li, Man-Zhi,Li, Yong,Zeng, Mu-Sheng Asian Pacific Journal of Cancer Prevention 2015 Asian Pacific journal of cancer prevention Vol.16 No.12

FADS1 (fatty acid desaturase 1) plays a crucial role in fatty acid metabolism, and it was recently reported to be involved in tumorigenesis. However, the role of FADS1 expression in esophageal squamous cell carcinoma (ESCC) remains unknown. In the current study, we investigated the expression and clinical pathologic and prognostic significance of FADS1 in ESCC. Immunohistochemical analyses revealed that 58.2% (146/251) of the ESCC tissues had low levels of FADS1 expression, whereas 41.8% (105/251) exhibited high levels of FADS1 expression. In positive cases, FADS1 expression was detected in the cytoplasm of cells. Correlation analyses demonstrated that FADS1 expression was significantly correlated with tumor location (p=0.025) but not with age, gender, histological grade, tumor status, nodal status or TNM staging. Furthermore, patients with tumors expressing high levels of FADS1had a longer disease-free survival time (p<0.001) and overall survival time (p <0.001). Univariate and multivariate analyses revealed that, along with nodal status, FADS1 expression was an independent and significant predictive factor (p<0.001). In conclusion, our study suggested that FADS1 might be a valuable biomarker and potential therapeutic target for ESCC.